United Lab (03933) has announced that its wholly-owned subsidiary Zhuhai United Laboratories Biopharmaceutical Co., Ltd. has received acceptance from China's National Medical Products Administration for the market registration application of Semaglutide Injection for the weight management indication, with acceptance numbers CXSS2600179, CXSS2600180, CXSS2600181, CXSS2600182, and CXSS2600183.
Semaglutide Injection is a long-acting recombinant human glucagon-like peptide-1 (GLP-1) analogue, primarily used in clinical settings for blood glucose control in patients with type 2 diabetes, long-term weight management for obese or overweight patients, reduction of major cardiovascular adverse event risk in obese or overweight patients, and treatment of MASH (metabolic dysfunction-associated steatohepatitis) in patients with moderate to severe liver fibrosis.
Administered via subcutaneous injection once weekly, it achieves significant weight loss through multiple mechanisms including appetite suppression, delayed gastric emptying, regulation of energy metabolism, and improvement of liver histology, while also providing comprehensive benefits such as reducing cardiovascular event risk and treating steatohepatitis with liver fibrosis, offering an efficient, convenient, and comprehensive long-term weight management solution for obese or overweight patients.
Previously, the company submitted the market registration application for Semaglutide Injection for the diabetes indication in January 2025, which was accepted. This market registration filing for the weight management indication further enriches the product's indication layout and is expected to bring clinical benefits to a broader patient population.
Around the GLP-1 target, the company has established a differentiated product pipeline combining innovative drugs and biosimilars, which helps enhance the company's market competitiveness in the biopharmaceutical field. In the future, the company will continue to dedicate itself to new product research and development, which is expected to create greater returns for the company and its shareholders.
Comments